Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention

Thrombosis Research

Volumn 128, Issue 6, 2011, Pages

  Ono, Takamichi ^a   Kaikita, Koichi ^a   Hokimoto, Seiji ^a   Iwashita, Satomi ^a   Yamamoto, Koichiro ^a   Miyazaki, Yuji ^a   Horio, Eiji ^a   Sato, Koji ^a   Tsujita, Kenichi ^a   Abe, Tomohide ^b   Deguchi, Mariko ^b   Tayama, Shinji ^a   Sumida, Hitoshi ^a   Sugiyama, Seigo ^a   Yamabe, Hiroshige ^a   Nakamura, Sunao ^a   Nakagawa, Kazuko ^b   Ogawa, Hisao ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

coronary artery disease; cut off level; CYP2C19; platelet aggregation; VerifyNow P2Y12 system

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CYTOCHROME P450 2C19; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTON PUMP INHIBITOR;

ADULT; AGED; ALLELE; ANALYTIC METHOD; ANTICOAGULANT THERAPY; ARTICLE; CORONARY ARTERY DISEASE; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; LIGHT TRANSMITTENT AGGREGOMETRY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; THROMBOCYTE AGGREGATION INHIBITION;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; ARYL HYDROCARBON HYDROXYLASES; ASPIRIN; CORONARY ARTERY DISEASE; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 82355169676     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.07.028     Document Type: Article

References (46)

1. S. Yusuf, F. Zhao, S.R. Mehta, S. Chrolavicius, G. Tognoni, and K.K. Fox Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502 (Pubitemid 32758501)
2. S.R. Mehta, S. Yusuf, R.J. Peters, M.E. Bertrand, B.S. Lewis, and M.K. Natarajan Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 2001 527 533 (Pubitemid 32772726)
3. S.R. Steinhubl, P.B. Berger, J.T. Mann III, E.T. Fry, A. DeLago, and C. Wilmer Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial JAMA 288 2002 2411 2420 (Pubitemid 35340537)
4. Z.M. Chen, L.X. Jiang, Y.P. Chen, J.X. Xie, H.C. Pan, and R. Peto Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial Lancet 366 2005 1607 1621
5. M.S. Sabatine, C.P. Cannon, C.M. Gibson, J.L. López-Sendón, G. Montalescot, and P. Theroux Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation N Engl J Med 352 2005 1179 1189 (Pubitemid 40397259)
6. R. Marcucci, A.M. Gori, R. Paniccia, B. Giusti, S. Valente, and C. Giglioli Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay Circulation 119 2009 237 242
7. S.D. Wiviott, E. Braunwald, C.H. McCabe, G. Montalescot, W. Ruzyllo, and S. Gottlieb Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015 (Pubitemid 350106708)
8. S.D. Wiviott, E. Braunwald, C.H. McCabe, I. Horvath, M. Keltai, and J.P. Herrman Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial Lancet 371 2008 1353 1363
9. P.A. Gurbel, K.P. Bliden, B.L. Hiatt, and C.M. O'Connor Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 2003 2908 2913 (Pubitemid 36736631)
10. M. O'Donoghue, and S.D. Wiviott Clopidogrel response variability and future therapies: clopidogrel: does one size fit all? Circulation 114 2006 e600 e606
11. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, F. Alfonso, C. Macaya, and T.A. Bass Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives J Am Coll Cardiol 49 2007 1505 1516 (Pubitemid 46517957)
12. S. Matetzky, B. Shenkman, V. Guetta, M. Shechter, R. Bienart, and I. Goldenberg Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 2004 3171 3175
13. W. Hochholzer, D. Trenk, H.P. Bestehorn, B. Fischer, C.M. Valina, and M. Ferenc Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement J Am Coll Cardiol 48 2006 1742 1750 (Pubitemid 44648629)
14. P.A. Gurbel, K.P. Bliden, W. Samara, J.A. Yoho, K. Hayes, and M.Z. Fissha Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study J Am Coll Cardiol 46 2005 1827 1832 (Pubitemid 41579803)
15. D. Trenk, W. Hochholzer, M.F. Fromm, L.E. Chialda, A. Pahl, and C.M. Valina Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents J Am Coll Cardiol 51 2008 1925 1934 (Pubitemid 351636443)
16. J.L. Rehmel, J.A. Eckstein, N.A. Farid, J.B. Heim, S.C. Kasper, and A. Kurihara Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450 Drug Metab Dispos 34 2006 600 607
17. M. Ingelman-Sundberg, S.C. Sim, A. Gomez, and C. Rodriguez-Antona Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects Pharmacol Ther 116 2007 496 526 (Pubitemid 350116943)
18. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, and J.T. Brandt Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
19. P.A. Gurbel, K.P. Bliden, K. Guyer, P.W. Cho, K.A. Zaman, and R.P. Kreutz Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study J Am Coll Cardiol 46 2005 1820 1826 (Pubitemid 41579802)
20. N.J. Breet, J.W. van Werkum, H.J. Bouman, J.C. Kelder, H.J. Ruven, and E.T. Bal Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation JAMA 303 2010 754 762
21. T. Sawada, T. Shinke, J. Shite, T. Honjo, Y. Haraguchi, and R. Nishio Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel Circ J 75 2010 99 105
22. B. Richards, J. Skoletsky, A.P. Shuber, R. Balfour, R.C. Stern, and H.L. Dorkin Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs Hum Mol Genet 2 1993 159 163 (Pubitemid 23075654)
23. T. Kubota, K. Chiba, and T. Ishizaki Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population Clin Pharmacol Ther 60 1996 661 666 (Pubitemid 27025913)
24. D.J. Angiolillo, E. Bernardo, D. Capodanno, D. Vivas, M. Sabaté, and J.L. Ferreiro Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy J Am Coll Cardiol 16 55 2010 1139 1146
25. S.D. Wiviott, E. Braunwald, D.J. Angiolillo, S. Meisel, A.J. Dalby, and F.W. Verheugt Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38 Circulation 118 2008 1626 1636
26. J.S. Berger, D.L. Bhatt, S.R. Steinhubl, M. Shao, P.G. Steg, and G. Montalescot Smoking, clopidogrel, and mortality in patients with established cardiovascular disease Circulation 120 2009 2337 2344
27. T. Gremmel, S. Steiner, D. Seidinger, R. Koppensteiner, S. Panzer, and C.W. Kopp Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel J Thromb Haemost 8 2010 37 42
28. P.M. Ho, T.M. Maddox, L. Wang, S.D. Fihn, R.L. Jesse, and E.D. Peterson Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome JAMA 301 2009 937 944
29. E.R. DeLong, D.M. DeLong, and D.L. Clarke-Pearson Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Biometrics 44 1988 837 845
30. Stata Base Reference Manual, (vol. 3). N-R, Release 8. College Station, Texas: Stata Press, Stata Corporation, 2003.
31. K. Yamamoto, S. Hokimoto, T. Chitose, K. Morita, T. Ono, and K. Kaikita Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy J Cardiol 57 2010 194 201
32. M.J. Price, S. Endemann, R.R. Gollapudi, R. Valencia, C.T. Stinis, and J.P. Levisay Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur Heart J 29 2008 992 1000 (Pubitemid 351844676)
33. G. Patti, A. Nusca, F. Mangiacapra, L. Gatto, A. D'Ambrosio, and G. Di Sciascio Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study J Am Coll Cardiol 52 2008 1128 1133
34. T. Geisler, H. Langer, M. Wydymus, K. Göhring, C. Zürn, and B. Bigalke Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation Eur Heart J 27 2006 2420 2425 (Pubitemid 44522148)
35. A. Malinin, A. Pokov, M. Spergling, A. Defranco, K. Schwartz, and D. Schwartz Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study Thromb Res 119 2007 277 284 (Pubitemid 44918092)
36. A. Malinin, A. Pokov, L. Swaim, M. Kotob, and V. Serebruany Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel Methods Find Exp Clin Pharmacol 28 2006 315 322 (Pubitemid 44047198)
37. J.L. Mega, T. Simon, J.P. Collet, J.L. Anderson, E.M. Antman, and K. Bliden Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis JAMA 304 2010 1821 1830
38. M.J. Price, P.B. Berger, P.S. Teirstein, J.F. Tanguay, D.J. Angiolillo, and D. Spriggs Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 11 Mar. 16 2011 1097 1105
39. R. Marcucci, A.M. Gori, R. Paniccia, B. Giusti, S. Valente, and C. Giglioli Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up Circulation 119 2009 237 242
40. G. Patti, A. Nusca, F. Mangiacapra, L. Gatto, A. D'Ambrosio, and G. Di Sciascio Point-ofcare measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study J Am Coll Cardiol 52 2008 1128 1133
41. M.J. Price, S. Endemann, R.R. Gollapudi, R. Valencia, C.T. Stinis, and J.P. Levisay Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur Heart J 29 2008 992 1000 (Pubitemid 351844676)
42. -2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2011 Writing Group Members et al. Circulation. (2011) Circulation 123 2011 2022 2060
43. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, F. Alfonso, C. Macaya, and T.A. Bass Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives J Am Coll Cardiol 49 2007 1505 1516 (Pubitemid 46517957)
44. J. Daemen, P. Wenaweser, K. Tsuchida, L. Abrecht, S. Vaina, and C. Morger Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study Lancet 369 2007 667 678 (Pubitemid 46281313)
45. J. Aoki, A.J. Lansky, R. Mehran, J. Moses, M.E. Bertrand, and B.T. McLaurin Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial Circulation 119 2009 687 698
46. T. Kimura, T. Morimoto, Y. Nakagawa, T. Tamura, K. Kadota, and H. Yasumoto Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation Circulation 119 2009 987 995